Aurora-A amplification associated with BRCA2 mutation in breast tumours

Cancer Letters

Volumn 248, Issue 1, 2007, Pages 96-102

  Bodvarsdottir, Sigridur K ^a,b   Hilmarsdottir, Holmfridur ^a,b   Birgisdottir, Valgerdur ^a,b   Steinarsdottir, Margret ^c   Jonasson, Jon G ^a,b,c   Eyfjord, Jorunn E ^a,b  

^a ICELANDIC CANCER SOCIETY   (Iceland)

^b UNIVERSITY OF ICELAND   (Iceland)

^c LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

Author keywords

Aurora A; BRCA2; Breast cancer; FISH; TP53

Indexed keywords

ARTICLE; AURORA A GENE; BRCA2 GENE; BREAST EPITHELIUM; BREAST TUMOR; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE AMPLIFICATION; GENE INTERACTION; GENE MUTATION; HUMAN; HUMAN TISSUE; METAPHASE CHROMOSOME; MUTATIONAL ANALYSIS; PRIORITY JOURNAL;

BRCA2 PROTEIN; BREAST NEOPLASMS; CELL LINE; DNA MUTATIONAL ANALYSIS; FEMALE; GENE AMPLIFICATION; HETEROZYGOTE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MUTATION; ODDS RATIO; PROTEIN-SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33847265438     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2006.06.003     Document Type: Article

References (40)

1. Nelson D.A., Tan T.T., Rabson A.B., Anderson D., Degenhardt K., and White E. Hypoxia and defective apoptosis drive genomic instability and tumorigenesis. Genes Dev. 18 17 (2004) 2095-2107
2. Sen S., Zhou H., and White R.A. A putative serine/threonine kinase encoding gene BTAK on chromosome 20q13 is amplified and overexpressed in human breast cancer cell lines. Oncogene 14 18 (1997) 2195-2200
3. Zhou H., Kuang J., Zhong L., Kuo W.L., Gray J.W., Sahin A., Brinkley B.R., and Sen S. Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat. Genet. 20 2 (1998) 189-193
4. Goepfert T.M., Adigun Y.E., Zhong L., Gay J., Medina D., and Brinkley W.R. Centrosome amplification and overexpression of aurora A are early events in rat mammary carcinogenesis. Cancer Res. 62 14 (2002) 4115-4122
5. Hoque A., Carter J., Xia W., Hung M.C., Sahin A.A., Sen S., and Lippman S.M. Loss of aurora A/STK15/BTAK overexpression correlates with transition of in situ to invasive ductal carcinoma of the breast. Cancer Epidemiol. Biomarkers Prev. 12 12 (2003) 1518-1522
6. Anand S., Penrhyn-Lowe S., and Venkitaraman A.R. AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. Cancer Cell 3 1 (2003) 51-62
7. Jiang Y., Zhang Y., Lees E., and Seghezzi W. AuroraA overexpression overrides the mitotic spindle checkpoint triggered by nocodazole, a microtubule destabilizer. Oncogene 22 51 (2003) 8293-8301
8. Gretarsdottir S., Thorlacius S., Valgardsdottir R., Gudlaugsdottir S., Sigurdsson S., Steinarsdottir M., Jonasson J.G., Anamthawat-Jonsson K., and Eyfjord J.E. BRCA2 and p53 mutations in primary breast cancer in relation to genetic instability. Cancer Res. 58 5 (1998) 859-862
9. Miyoshi Y., Iwao K., Takahashi Y., Egawa C., and Noguchi S. Acceleration of chromosomal instability by loss of BRCA1 expression and p53 abnormality in sporadic breast cancers. Cancer Lett. 159 2 (2000) 211-216
10. Eyfjord J.E., and Bodvarsdottir S.K. Genomic instability and cancer: networks involved in response to DNA damage. Mutat. Res. 592 1-2 (2005) 18-28
11. Bergthorsson J.T., Jonasdottir A., Johannesdottir G., Arason A., Egilsson V., Gayther S., Borg A., Hakanson S., Ingvarsson S., and Barkardottir R.B. Identification of a novel splice-site mutation of the BRCA1 gene in two breast cancer families: screening reveals low frequency in Icelandic breast cancer patients. Hum. Mutat. Suppl. 1 (1998) S195-S197
12. Thorlacius S., Olafsdottir G., Tryggvadottir L., Neuhausen S., Jonasson J.G., Tavtigian S.V., Tulinius H., Ogmundsdottir H.M., and Eyfjord J.E. A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat. Genet. 13 1 (1996) 117-119
13. Thorlacius S., Sigurdsson S., Bjarnadottir H., Olafsdottir G., Jonasson J.G., Tryggvadottir L., Tulinius H., and Eyfjord J.E. Study of a single BRCA2 mutation with high carrier frequency in a small population. Am. J. Hum. Genet. 60 5 (1997) 1079-1084
14. Mikaelsdottir E.K., Valgeirsdottir S., Eyfjord J.E., and Rafnar T. The Icelandic founder mutation BRCA2 999del5: analysis of expression. Breast Cancer Res. 6 4 (2004) R284-R290
15. Tutt A., Gabriel A., Bertwistle D., Connor F., Paterson H., Peacock J., Ross G., and Ashworth A. Absence of Brca2 causes genome instability by chromosome breakage and loss associated with centrosome amplification. Curr. Biol. 9 19 (1999) 1107-1110
16. Lee H., Trainer A.H., Friedman L.S., Thistlethwaite F.C., Evans M.J., Ponder B.A., and Venkitaraman A.R. Mitotic checkpoint inactivation fosters transformation in cells lacking the breast cancer susceptibility gene, Brca2. Mol. Cell 4 1 (1999) 1-10
17. Daniels M.J., Wang Y., Lee M., and Venkitaraman A.R. Abnormal cytokinesis in cells deficient in the breast cancer susceptibility protein BRCA2. Science 306 5697 (2004) 876-879
18. Fukasawa K., Choi T., Kuriyama R., Rulong S., and Vande Woude G.F. Abnormal centrosome amplification in the absence of p53. Science 271 5256 (1996) 1744-1747
19. Chen S.S., Chang P.C., Cheng Y.W., Tang F.M., and Lin Y.S. Suppression of the STK15 oncogenic activity requires a transactivation-independent p53 function. EMBO J. 21 17 (2002) 4491-4499
20. Zhang D., Hirota T., Marumoto T., Shimizu M., Kunitoku N., Sasayama T., Arima Y., Feng L., Suzuki M., Takeya M., and Saya H. Cre-loxP-controlled periodic Aurora-A overexpression induces mitotic abnormalities and hyperplasia in mammary glands of mouse models. Oncogene 23 54 (2004) 8720-8730
21. Meraldi P., Honda R., and Nigg E.A. Aurora-A overexpression reveals tetraploidization as a major route to centrosome amplification in p53-/- cells. EMBO J. 21 4 (2002) 483-492
22. Katayama H., Sasai K., Kawai H., Yuan Z.M., Bondaruk J., Suzuki F., Fujii S., Arlinghaus R.B., Czerniak B.A., and Sen S. Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Nat. Genet. 36 1 (2004) 55-62
23. Liu Q., Kaneko S., Yang L., Feldman R.I., Nicosia S.V., Chen J., and Cheng J.Q. Aurora-A abrogation of p53 DNA binding and transactivation activity by phosphorylation of serine 215. J. Biol. Chem. 279 50 (2004) 52175-52182
24. Jeng Y.M., Peng S.Y., Lin C.Y., and Hsu H.C. Overexpression and amplification of Aurora-A in hepatocellular carcinoma. Clin. Cancer Res. 10 6 (2004) 2065-2071
25. Gudmundsdottir K., Thorlacius S., Jonasson J.G., Sigfusson B.F., Tryggvadottir L., and Eyfjord J.E. CYP17 promoter polymorphism and breast cancer risk in males and females in relation to BRCA2 status. Br. J. Cancer 88 6 (2003) 933-936
26. Gudlaugsdottir S., Sigurdardottir V., Snorradottir M., Jonasson J.G., Ogmundsdottir H., and Eyfjord J.E. P53 mutations analysis in benign and malignant breast lesions: using needle rinses from fine-needle aspirations. Diagn. Cytopathol. 22 5 (2000) 268-274
27. Rubner Fridriksdottir A.J., Gudjonsson T., Halldorsson T., Bjornsson J., Steinarsdottir M., Johannsson O.T., and Ogmundsdottir H.M. Establishment of three human breast epithelial cell lines derived from carriers of the 999del5 BRCA2 Icelandic founder mutation. In Vitro Cell Dev. Biol. Anim. 41 10 (2005) 337-342
28. Tirkkonen M., Johannsson O., Agnarsson B.A., Olsson H., Ingvarsson S., Karhu R., Tanner M., Isola J., Barkardottir R.B., Borg A., and Kallioniemi O.P. Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Res. 57 7 (1997) 1222-1227
29. van Beers E.H., van Welsem T., Wessels L.F., Li Y., Oldenburg R.A., Devilee P., Cornelisse C.J., Verhoef S., Hogervorst F.B., van't Veer L.J., and Nederlof P.M. Comparative genomic hybridization profiles in human BRCA1 and BRCA2 breast tumors highlight differential sets of genomic aberrations. Cancer Res. 65 3 (2005) 822-827
30. Jonsson G., Naylor T.L., Vallon-Christersson J., Staaf J., Huang J., Ward M.R., Greshock J.D., Luts L., Olsson H., Rahman N., Stratton M., Ringner M., Borg A., and Weber B.L. Distinct genomic profiles in hereditary breast tumors identified by array-based comparative genomic hybridization. Cancer Res. 65 17 (2005) 7612-7621
31. Krystyniak A., Garcia-Echeverria C., Prigent C., and Ferrari S. Inhibition of Aurora A in response to DNA damage. Oncogene 25 3 (2006) 338-348
32. Cazales M., Schmitt E., Montembault E., Dozier C., Prigent C., and Ducommun B. CDC25B phosphorylation by Aurora-A occurs at the G2/M transition and is inhibited by DNA damage. Cell Cycle 4 9 (2005) 1233-1238
33. Hirota T., Kunitoku N., Sasayama T., Marumoto T., Zhang D., Nitta M., Hatakeyama K., and Saya H. Aurora-A an interacting activator the LIM protein Ajuba are required for mitotic commitment in human cells. Cell 114 5 (2003) 585-598
34. Dutertre S., Cazales M., Quaranta M., Froment C., Trabut V., Dozier C., Mirey G., Bouche J.P., Theis-Febvre N., Schmitt E., Monsarrat B., Prigent C., and Ducommun B. Phosphorylation of CDC25B by Aurora-A at the centrosome contributes to the G2-M transition. J. Cell Sci. 117 Pt 12 (2004) 2523-2531
35. De Souza C.P., Ellem K.A., and Gabrielli B.G. Centrosomal and cytoplasmic Cdc2/cyclin B1 activation precedes nuclear mitotic events. Exp. Cell Res. 257 1 (2000) 11-21
36. Palacios J., Honrado E., Osorio A., Cazorla A., Sarrio D., Barroso A., Rodriguez S., Cigudosa J.C., Diez O., Alonso C., Lerma E., Dopazo J., Rivas C., and Benitez J. Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers. Breast Cancer Res. Treat 90 1 (2005) 5-14
37. Tarapore P., Horn H.F., Tokuyama Y., and Fukasawa K. Direct regulation of the centrosome duplication cycle by the p53-p21Waf1/Cip1 pathway. Oncogene 20 25 (2001) 3173-3184
38. Ditchfield C., Johnson V.L., Tighe A., Ellston R., Haworth C., Johnson T., Mortlock A., Keen N., and Taylor S.S. Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores. J. Cell Biol. 161 2 (2003) 267-280
39. Heron N.M., Anderson M., Blowers D.P., Breed J., Eden J.M., Green S., Hill G.B., Johnson T., Jung F.H., McMiken H.H., Mortlock A.A., Pannifer A.D., Pauptit R.A., Pink J., Roberts N.J., and Rowsell S. SAR and inhibitor complex structure determination of a novel class of potent and specific Aurora kinase inhibitors. Bioorg. Med. Chem. Lett 16 5 (2006) 1320-1323
40. Harrington E.A., Bebbington D., Moore J., Rasmussen R.K., Ajose-Adeogun A.O., Nakayama T., Graham J.A., Demur C., Hercend T., Diu-Hercend A., Su M., Golec J.M., and Miller K.M. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat. Med. 10 3 (2004) 262-267